By studying PRMT1 knockdown alone and in combination with oncogene-targeting drugs, we found that suppression of oncogenic signaling in lung cancer confers a collateral dependency on PRMT1 in persistent cancer cells. The gene discussed is PRMT1; the disease is lung cancer.